diclofenac and plx4032

diclofenac has been researched along with plx4032 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Arenberger, P; Arenbergerova, M; Dvorak, J; Ettler, J; Fialova, A; Gkalpakiotis, S; Srp, A	1
Blank, C; Brummer, C; Bruss, C; Faerber, S; Haferkamp, S; Herr, W; Kreutz, M; Lacroix, R; Renner, K	1

Other Studies

2 other study(ies) available for diclofenac and plx4032

Article	Year
Severe diclofenac photoallergy in a patient treated with vemurafenib. Journal of the European Academy of Dermatology and Venereology : JEADV, 2016, Volume: 30, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Diclofenac; Female; Humans; Indoles; Middle Aged; Sulfonamides; Vemurafenib	2016
Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma. Cancer letters, 2019, 02-01, Volume: 442 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Diclofenac; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Energy Metabolism; Genetic Predisposition to Disease; Humans; Melanoma; Mitogen-Activated Protein Kinases; Mutation; Phenotype; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Signal Transduction; Skin Neoplasms; Time Factors; Vemurafenib	2019

Article

Year

Severe diclofenac photoallergy in a patient treated with vemurafenib.

Journal of the European Academy of Dermatology and Venereology : JEADV, 2016, Volume: 30, Issue:4

Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Diclofenac; Female; Humans; Indoles; Middle Aged; Sulfonamides; Vemurafenib

2016

Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.

Cancer letters, 2019, 02-01, Volume: 442

Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Diclofenac; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Energy Metabolism; Genetic Predisposition to Disease; Humans; Melanoma; Mitogen-Activated Protein Kinases; Mutation; Phenotype; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Signal Transduction; Skin Neoplasms; Time Factors; Vemurafenib

2019